After capping off a transformative 2025, Xeris Biopharma Holdings Inc. (XERS) entered 2026 with strong commercial momentum, backed by a solid balance sheet and a disciplined strategy aimed at driving sustained long-term growth across the business. What can investors expect from Xeris this year?
The company markets Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com